Cryptogenic fibrosing alveolitis (CFA) in post-delivery period - the results of the long-term study Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001
The features of the course of cryptogenic fibrosing alveolitis in women Source: Eur Respir J 2002; 20: Suppl. 38, 59s Year: 2002
Hemostasis disorders and their correction using ticlopidine in patients with cryptogenic fibrosing alveolitis (CFA) Source: Eur Respir J 2003; 22: Suppl. 45, 84s Year: 2003
Hemocoagulation and platelet aggregation disorders in patients with cryptogenic fibrosing alveolitis (CFA) Source: Eur Respir J 2002; 20: Suppl. 38, 226s Year: 2002
Outcomes of fibrosing alveolitis. Long-term follow-up Source: Eur Respir J 2001; 18: Suppl. 33, 385s Year: 2001
Lung cancer in patients with cryptogenic fibrosing alveolitis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008
Specific features of the course of cryptogenic fibrosing alveolitis in pregnancy Source: Eur Respir J 2001; 18: Suppl. 33, 150s Year: 2001
The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up) Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010
Cytokine regulation in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis: clinicomorphological study Source: Eur Respir J 2001; 18: Suppl. 33, 107s Year: 2001
Familial case of cryptogenic fibrosing alveolitis in two siblings Source: Eur Respir J 2001; 18: Suppl. 33, 219s Year: 2001
Fibrosing alveolitis in rheumatoid arthritis (FARA):a survival comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) Source: Eur Respir J 2003; 22: Suppl. 45, 197s Year: 2003
Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Parameters of antioxidant protection in patients with cryptogenic fibrosing alveolitis Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007
Acute exacerbation admissions of fibrosing interstitial lung diseases – 3 years study Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019
Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Source: Eur Respir Rev 2012 21: 355-361 Year: 2012
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012
Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: 43S-55S Year: 2001
Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021
A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
CT features of fibrosing alveolitis in rheumatoid arthritis (FARA): a comparison with idiopathic usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP) Source: Eur Respir J 2003; 22: Suppl. 45, 197s Year: 2003